Portfoliotracker

ABIVAX Société Anonyme

ABVX · NASDAQGM · Healthcare Biotechnology 21/100 E

83,61 $
▼ −3,97 (−4,53 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:10
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score21 / 100 Market cap7,67 mld. $ P/E– Forward P/E-22,8 P/S1 642,4 P/B17,0 EV/EBITDA-22,6 Dividend yield– FCF yield– EPS-6,08 $ Net margin0,0 % Return on equity-252,3 % Beta-0,33 Debt / equity0,00
52-week range 69,81 to 148,83
3-month average volume1,1 M

We do not have financial statements yet

The company reports in EUR, while the price is quoted in USD. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Website
abivax.com
Employees
98
Country
France
Data since
20. 10. 2023

Explore further

Similar companies CELCPRAXALMSTNGXGPCR

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account